Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 832,987
  • Shares Outstanding, K 131,179
  • Annual Sales, $ 25,550 K
  • Annual Income, $ -341,970 K
  • 60-Month Beta 1.63
  • Price/Sales 30.30
  • Price/Cash Flow N/A
  • Price/Book 1.01
Trade RLAY with:

Options Overview Details

View History
  • Implied Volatility 146.24% ( -8.32%)
  • Historical Volatility 65.73%
  • IV Percentile 95%
  • IV Rank 43.64%
  • IV High 269.51% on 10/20/23
  • IV Low 50.77% on 01/08/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 52
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 843
  • Open Int (30-Day) 755

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.70
  • Number of Estimates 7
  • High Estimate -0.63
  • Low Estimate -0.86
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +10.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.70 +7.98%
on 04/24/24
8.43 -26.99%
on 03/28/24
-1.38 (-18.26%)
since 03/25/24
3-Month
5.70 +7.98%
on 04/24/24
11.16 -44.85%
on 02/16/24
-3.70 (-37.51%)
since 01/25/24
52-Week
5.70 +7.98%
on 04/24/24
13.32 -53.79%
on 07/12/23
-5.62 (-47.75%)
since 04/25/23

Most Recent Stories

More News
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,048.42 (-0.46%)
NVO : 125.79 (-0.29%)
BIIB : 202.46 (+0.23%)
KNSA : 17.61 (-1.40%)
SWTX : 44.20 (+1.89%)
RLAY : 6.16 (-3.07%)
ADPT : 2.61 (+0.38%)
GS : 420.05 (-0.71%)
Unlocking AI investment opportunities in healthcare

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 35.11 (+1.77%)
NVDA : 826.32 (+3.71%)
RXRX : 7.84 (-1.26%)
RLAY : 6.16 (-3.07%)
EXAI : 3.99 (-3.39%)
RENB : 1.7000 (-13.71%)
BTAI : 2.61 (-3.69%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END

ONCY : 1.0800 (+1.89%)
ONC.TO : 1.49 (+1.36%)
PFE : 25.26 (-3.84%)
OCEA : 1.2550 (-11.31%)
NVS : 99.06 (+0.72%)
RLAY : 6.16 (-3.07%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

/PRNewswire/ -- Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from...

ONC.TO : 1.49 (+1.36%)
ONCY : 1.0800 (+1.89%)
PFE : 25.26 (-3.84%)
OCEA : 1.2550 (-11.31%)
NVS : 99.06 (+0.72%)
RLAY : 6.16 (-3.07%)
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RLAY : 6.16 (-3.07%)
MKGAF : 165.3300 (+4.40%)
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RLAY : 6.16 (-3.07%)
UTHR : 235.95 (-0.44%)
Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

RLAY : 6.16 (-3.07%)
CPRX : 14.68 (-2.91%)
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effectiveness of this highly sought-after metric is questionable,...

RLAY : 6.16 (-3.07%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2023 – USA News Group  –  Treatments for various forms of breast cancer continue to evolve, with several new...

BCTX : 2.24 (+2.28%)
ONCY : 1.0800 (+1.89%)
ONC.TO : 1.49 (+1.36%)
CTMX : 1.6000 (-1.84%)
BCT.TO : 3.01 (+0.33%)
RLAY : 6.16 (-3.07%)
HOLX : 75.71 (-1.30%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 0.9419 (+4.66%)
ONC.TO : 1.49 (+1.36%)
BCT.TO : 3.01 (+0.33%)
ONCY : 1.0800 (+1.89%)
CTMX : 1.6000 (-1.84%)
BCTX : 2.24 (+2.28%)
RLAY : 6.16 (-3.07%)
HOLX : 75.71 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 6.69
2nd Resistance Point 6.45
1st Resistance Point 6.30
Last Price 6.16
1st Support Level 5.91
2nd Support Level 5.67
3rd Support Level 5.52

See More

52-Week High 13.32
Fibonacci 61.8% 10.41
Fibonacci 50% 9.51
Fibonacci 38.2% 8.61
Last Price 6.16
52-Week Low 5.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar